Strike two: Au­ris shares crushed again as its sec­ond PhI­II pro­gram fails to de­liv­er

Au­ris Med­ical has lurched from a failed late-stage study of its ex­per­i­men­tal tin­ni­tus drug last year to a Phase III flop for its hear­ing loss ther­a­py. And once again, it’s claim­ing that a change­up in tri­al de­sign could fix every­thing.

The Swiss biotech $EARS test­ed two dos­es of AM-111 in pa­tients with se­vere to pro­found sud­den deaf­ness, and both failed to achieve sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ments for the peo­ple who took the drug com­pared to a place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER